CVS Health Corp. (CVS) Stock Analysis
Latest ClaritX AI analysis ·
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was f
| Metric | Value |
|---|---|
| Price | $94.07 |
| Market cap | $120.3B |
| Sector | Healthcare |
| Industry | Medical - Healthcare Plans |
| ClaritX AI score | 83/100 |
| Price/Book | 1.51 |
| Dividend yield | 2.83% |
| Beta | 0.60 |
AI verdict
CVS Health Corporation presents a highly compelling, risk-adjusted investment thesis that elegantly weds elite free cash flow generation with a structurally confirmed technical breakout. Currently priced at $94.07, the equity is positioned roughly 15% below its established 52-week high of $110.68. Applying rigorous risk management principles, accumulating a heavily insulated, vertically integrated healthcare conglomerate boasting an exceptionally low beta of 0.596 at a significant discount from its peak substantially de-risks the entry point for patient capital. This stands in stark contrast to chasing highly speculative, high-beta momentum equities at euphoric market tops, where downside risk is dangerously asymmetrical. The enterprise generates a phenomenal $9.21 in FCF per share, effortlessly covering its 2.82% dividend yield with an ultra-safe 28.8% cash payout ratio. Crucially, the structural narrative has pivoted from defensive recovery to offensive expansion. Having entirely eliminated the massive DOJ opioid litigation overhang, the market is now aggressively pricing in the firm's operational momentum—specifically Aetna's improved efficiencies and the strategic absorption of market share from failing retail competitors like Walgreens. While an overbought RSI of 78.03 signals the potential for a near-term horizontal breather, the firm's flawless 5/5 DCF valuation, deeply distressed 0.289x Price-to-Sales multiple, and sustained positioning above the 200-day moving avera
What this score has been worth
ClaritX scores CVS 83 out of 100 (snapshot 2026-10-21).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 193 analyses that scored in the 80-84 band, the average forward return was -0.3% with a 50% win rate, -5.1pp against the S&P 500. That is a measured tendency across many names, not a forecast for CVS — roughly 50% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.